a privately held biopharmaceutical company developing particle-based vaccines
and therapeutics, today announced it has completed a $20 million round of Series
C financing. Canaan Partners led the Series C round, which also included Pappas
Ventures and Morningside Venture Investments Limited as new investors. Previous
investors, including New Enterprise Associates and Firelake Capital, also participated
in the financing round. The funds will be used to accelerate Liquidia’s
lead vaccine candidate through initial clinical evaluation and expand development
of particle-based solutions for siRNA delivery and inhaled therapeutics.
"This additional funding provides further validation of Liquidia’s
leadership in the development of particle-based vaccines and therapeutics,"
said Neal Fowler, CEO of Liquidia Technologies. "We are pleased to attract
excellent investors and a tremendous level of interest in the PRINT® platform
as a result of our progress.”
As part of the Series C financing, Stephen Bloch, MD, a General Partner with
Canaan Partners, and Isaac Cheng, MD, with Morningside Technology Advisory LLC,
have joined the Liquidia Board of Directors.
“We are very excited to support the development of Liquidia’s initial
product and help fuel the next stage of growth for Liquidia,” said Dr.
Bloch, of Canaan Partners. “The company’s PRINT platform technology
represents a paradigm shift for the design and development of innovative vaccines
and therapeutics, opening the doors to unprecedented control over drug product
Liquidia Technologies is a privately-held biopharmaceutical company that develops
and manufactures precisely engineered particles for improved delivery of biological
and small molecule therapeutics. The company is currently advancing programs
within the fields of vaccines, nucleic acid delivery, and inhaled therapeutics
to address critical unmet needs in the treatment of human disease.